VPI-2690B is a human-derived monoclonal antibody (mAb) that targets Integrin alphaVbeta3. It is capable of modulating TGF-beta signaling and can be utilized in research related to diabetic nephropathy.
Target:
Integrin|||TGF-beta/Smad
* VAT and and shipping costs not included. Errors and price changes excepted